Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep;11(9):1742-1762.
doi: 10.21037/tlcr-22-617.

International expert consensus on immunotherapy for early-stage non-small cell lung cancer

Wenhua Liang  1 Kaican Cai  2 Qingdong Cao  3 Chun Chen  4 Haiquan Chen  5 Jun Chen  6 Ke-Neng Chen  7 Qixun Chen  8   9 Tianqing Chu  10 Yuchao Dong  11 Jiang Fan  12   13 Wentao Fang  14 Junke Fu  15 Xiangning Fu  16 Shugeng Gao  17 Di Ge  18 Guojun Geng  19 Qing Geng  20 Jie He  17 Jian Hu  21 Jie Hu  22 Wei-Dong Hu  23 Feng Jiang  24 Tao Jiang  25 Wenjie Jiao  26 He-Cheng Li  27 Qiang Li  28 Shanqing Li  29 Shuben Li  1 Xiangnan Li  30 Yong-De Liao  31 Changhong Liu  32 Hongxu Liu  33 Yang LiuZhuming LuQingquan Luo  34 Haitao Ma  35 Xiaojie Pan  36 Guibin Qiao  37 Shengxiang Ren  38 Weiyu Shen  39 Yong Song  40 Daqiang Sun  41 Guangsuo Wang  42 Jie Wang  43 Mengzhao Wang  44 Qiwen Wang  45 Wen-Xiang Wang  46 Li Wei  47 Ming Wu  48 Nan Wu  49 Hui Xia  50 Shi-Dong Xu  51 Fan Yang  52 Kang Yang  53 Yue Yang  54 Fenglei Yu  55 Zhen-Tao Yu  56 Dong-Sheng Yue  57 Lanjun Zhang  58 Weidong Zhang  59 Zhenfa Zhang  60 Guofang Zhao  61 Jian Zhao  62 Xiaojing Zhao  63 Chengzhi Zhou  64 Qinghua Zhou  65 Kunshou Zhu  66 Yuming Zhu  67 Toyoaki Hida  68 Wolfram C M Dempke  69 Antonio Rossi  70 Marc de Perrot  71 Robert A Ramirez  72 Mariano Provencio  73 Jay M Lee  74 Antonio Passaro  75 Lorenzo Spaggiari  76   77 Jonathan Spicer  78 Nicolas Girard  79 Patrick M Forde  80 Tony S K Mok  81 Tina Cascone  82 Jianxing He  1
Affiliations
Review

International expert consensus on immunotherapy for early-stage non-small cell lung cancer

Wenhua Liang et al. Transl Lung Cancer Res. 2022 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-22-617/coif). TH serves as an unpaid editorial board member of Translational Lung Cancer Research from January 2022 to December 2023. AR serves as an unpaid editorial board member of Translational Lung Cancer Research from November 2020 to October 2022. RAR serves as an unpaid editorial board member of Translational Lung Cancer Research from January 2022 to December 2023. MP serves as an unpaid editorial board member of Translational Lung Cancer Research from October 2021 to September 2023. RAR has been a consultant for Amgen, Ipsen Biopharmaceuticals, Novartis, Advanced Accelerator Applications, Curium Pharma, EMD Serono, Astra-Zeneca. He has also received research funding (to institution) from Merck & Co and Aadi Biosciences. He is also on the speaker bureaus for Ipsen Biopharmaceuticals and Astra-Zeneca. Mariano Provencio received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events and consulting fees from BMS, Astra Zéneca, MSD, Roche, Takeda and Pfizer. Jay M. Lee reports advisory board/consultant of Astrazeneca, Bristol Myers Squibb, Genentech, Novartis, Roche; research support from Genentech, Novartis; steering committee of Genentech, Novartis; speaker’s bureau of AstraZeneca, Genentech, Roche; stock from Moderna; patents of UCLA. Antonio Passaro received honoraria for consulting, advisory role or lectures from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Jansenn, Merck Sharp & Dohme, Roche Genentech, Novartis, MundiPharma, Daiichi Sankyo, eCancer and Medscape. TC reports speaker fees/honoraria from The Society for Immunotherapy of Cancer, Bristol Myers Squibb, Roche, Medscape, and PeerView; travel, food and beverage expenses from Dava Oncology; advisory role/consulting fees from AstraZeneca, Bristol Myers Squibb, EMD Serono, Merck & Co., Genentech, and Arrowhead Pharmaceuticals; and institutional research funding from AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim and EMD Serono. The other authors have no conflicts of interest to declare.

Similar articles

Cited by

References

    1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209-49. 10.3322/caac.21660 - DOI - PubMed
    1. Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl) 2021;134:783-91. 10.1097/CM9.0000000000001474 - DOI - PMC - PubMed
    1. Zheng RS, Sun KX, Zhang SW, et al. Report of cancer epidemiology in China, 2015. Zhonghua Zhong Liu Za Zhi 2019;41:19-28. - PubMed
    1. Reck M, Rabe KF. Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer. N Engl J Med 2017;377:849-61. 10.1056/NEJMra1703413 - DOI - PubMed
    1. Uramoto H, Tanaka F. Recurrence after surgery in patients with NSCLC. Transl Lung Cancer Res 2014;3:242-9. - PMC - PubMed